UNSPSC 51434401: Mecamylamine

This classification denotes a nicotinic antagonist with the molecular formula C11H21N, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6EE945D3OK, chemically known as 3-beta-methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane but generally known as mecamylamine, which bears US NIH Compound Identifier 4032. European Medicines Agency schedules Mecamylamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08670MIG.

UNSPSC 51434401 Mecamylamine, a Commodity code, represents pharmaceutical supply procurement by state and local health and human services agencies, though the recent opportunities block shows this specific drug appearing only peripherally in broader advanced-life-support medication and generic-pharmaceutical contracts. State and local governments buy under this code when stocking emergency response protocols, public health programs, and state employee or Medicaid pharmacy benefits. The issuing bodies include municipal fire and rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate procurement across member jurisdictions. Work solicited under the code ranges from individual medication line items bundled with other drugs (as in emergency-response kits) to manufacturer-direct supply arrangements negotiated through pharmacy benefit consolidation programs.

Recent activity spans Florida, Texas, and Minnesota-led multistate purchasing. The City of Tampa Fire Rescue issued IFB 26P00188 (due April 8, 2026) for Advanced Life Support Medications including epinephrine, adenosine, labetalol, and diltiazem, with an estimated contract value of $40,000 and a one-year term plus two renewal options; the solicitation carried a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 (April 3, 2026 response deadline) to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson), with a two-year contract term, evaluation weighted 75 percent on price competitiveness, and participation by Oregon and other member states.